3 citations
,
March 1998 in “PubMed” A woman's skin and hair conditions improved after her cancerous tumor was removed.
71 citations
,
May 1975 in “The American journal of surgery” The patient's liver did not fully grow back and she had serious temporary side effects after a very large liver surgery.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
7 citations
,
August 2022 in “Experimental dermatology” Blocking YAP/TAZ could be a new way to treat skin cancer.
March 2014 in “Journal of The American Academy of Dermatology” Terbinafine 250 mg is the most effective treatment for fungal nail infections.
6 citations
,
June 1983 in “Cancer” A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology”
Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.
Keratinocytes can reduce the survival of certain melanoma cells, suggesting new therapy paths.
January 2008 in “xPharm: The Comprehensive Pharmacology Reference” January 2026 in “International Journal of Dermatology” Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
June 2026 in “Strathprints: The University of Strathclyde institutional repository (University of Strathclyde)” Topical IKKα inhibitors may help prevent CCS tumours.
41 citations
,
November 1987 in “British Journal of Dermatology” Ketoconazole cured about 70% of cutaneous leishmaniasis cases caused by Leishmania major.
9 citations
,
November 1991 in “American Journal of Kidney Diseases” December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
Hair loss from immunosuppressive drugs in transplant patients can affect well-being and treatment adherence, so personalized management is important.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
April 2023 in “Journal of Investigative Dermatology” Radiation treatment causes skin fibrosis by increasing certain fibroblast subpopulations, but using a c-Jun inhibitor or fat grafting can reduce this effect.
10 citations
,
October 2010 in “Hepatology” Certain liver diseases respond well to specific treatments and have varying risks for liver cancer.
1 citations
,
January 2012 in “Zhongguo shiyan fangjixue zazhi” Kang'ai injection with FLO chemotherapy improves effectiveness and quality of life in advanced gastric cancer patients.
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
January 2023 in “Cutaneous and Ocular Toxicology”
9 citations
,
November 2012 in “Hepatology Research” A man lost all his hair permanently after hepatitis C treatment, a side effect not seen before.
5 citations
,
April 2019 in “Journal of Investigative Dermatology” Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
12 citations
,
July 2023 in “Journal of the European Academy of Dermatology and Venereology” Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
February 2022 in “Research Square (Research Square)” Certain nutraceuticals may enhance hair growth without affecting the cancer-fighting properties of tamoxifen.
November 2025 in “Journal of Investigative Dermatology”